Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis.
Vandeghinste N, Klattig J, Jagerschmidt C, Lavazais S, Marsais F, Haas JD, Auberval M, Lauffer F, Moran T, Ongenaert M, Van Balen M, Dupont S, Lepescheux L, Garcia T, Härtle S, Eyerich K, Fallon PG, Brys R, Steidl S. Vandeghinste N, et al. Among authors: hartle s. J Invest Dermatol. 2018 Jul;138(7):1555-1563. doi: 10.1016/j.jid.2018.01.036. Epub 2018 Feb 21. J Invest Dermatol. 2018. PMID: 29474945 Free article.
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, Einsele H, Ferstl B, Schub N, Röllig C, Weisel K, Winderlich M, Griese J, Härtle S, Weirather J, Jarutat T, Peschel C, Chatterjee M. Raab MS, et al. Among authors: hartle s. Lancet Haematol. 2020 May;7(5):e381-e394. doi: 10.1016/S2352-3026(19)30249-2. Epub 2020 Mar 11. Lancet Haematol. 2020. PMID: 32171061 Clinical Trial.
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
Mayer KA, Budde K, Halloran PF, Doberer K, Rostaing L, Eskandary F, Christamentl A, Wahrmann M, Regele H, Schranz S, Ely S, Firbas C, Schörgenhofer C, Kainz A, Loupy A, Härtle S, Boxhammer R, Jilma B, Böhmig GA. Mayer KA, et al. Among authors: hartle s. Trials. 2022 Apr 8;23(1):270. doi: 10.1186/s13063-022-06198-9. Trials. 2022. PMID: 35395951 Free PMC article.
Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.
Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B. Rovin BH, et al. Among authors: hartle s. Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. eCollection 2024 Sep. Kidney Int Rep. 2024. PMID: 39291206 Free PMC article.
Adapting the SMART tube technology for flow cytometry in feline full blood samples.
Zwicklbauer K, von la Roche D, Krentz D, Kolberg L, Alberer M, Zablotski Y, Hartmann K, von Both U, Härtle S. Zwicklbauer K, et al. Among authors: hartle s. Front Vet Sci. 2024 Jun 26;11:1377414. doi: 10.3389/fvets.2024.1377414. eCollection 2024. Front Vet Sci. 2024. PMID: 38988976 Free PMC article.
41 results